Table of Contents
Introduction:
Sustaining optimal health primarily involves keeping the body's iron levels in the appropriate balance. Despite this, a lot of people lack or have too much of this one basic component. When iron levels are too high, it eventually becomes stored in different tissues, which can lead to localized harm. Iron homeostasis is an essential mechanism that helps reduce oxidative stress, tissue degeneration, and cellular deterioration. Systemic iron chelation therapy has been around for a while to treat iron overload and helps bring iron levels back to appropriate homeostatic concentrations. Topical iron chelation therapy has become a viable treatment option for skin damage in recent times.
What Is Iron Overload?
A prevalent clinical issue, iron overload can result from chronic blood transfusions for a variety of blood illnesses or from disorders with elevated iron absorption, such as thalassemia intermedia syndromes (a hereditary blood disorder impacting hemoglobin formation) or hereditary hemochromatosis (a hereditary condition that makes the body absorb excessive amounts of iron from meals). Chronic blood transfusion therapy invariably results in secondary iron overload, which can seriously harm the endocrine system as well as other organs. Free radicals produced by iron overload can harm tissues, leading to endocrine disruption, liver toxicity, and heart toxicity. When individuals already have diabetes, cirrhosis, liver disease, cardiomyopathy, or other conditions that cause harm, the consequences of iron overload become apparent.
The body needs iron and physiological processes strictly control its amount. Nevertheless, the body lacks a way to get rid of extra iron, so it builds it up in the end organs, which can cause serious dysfunction. When there is an iron excess, the body continuously produces labile plasma iron (LPI), a toxic and chelate type of iron that has been connected to the emergence of concurrent medical conditions. To prevent the severe clinical consequences linked to iron overload, it is crucial to eliminate extra iron and decrease LPI.
What Is Iron Chelation Therapy?
Chelation therapy's primary goal is to eradicate and avoid iron excess completely. Chelation can remove excess iron from the body and maintain normal iron levels. Iron chelator therapy can lessen the harmful effects of iron excess in patients. Effective chelation therapy combined with direct acquisition of non-transferrin-bound iron and LPI may assist in mitigating the negative effects of iron overload. Numerous iron chelators have been created, to mobilize tissue iron by the formation of complexes that are eliminated in the urine and feces.
The three iron chelators that have been approved for clinical use by the US Food and Drug Administration are Deferoxamine (DFO), Deferiprone (DFP), and Deferasirox (DFX). It is widely recognized that each of these iron chelators can effectively treat iron overload in a range of clinical settings.
Iron chelation treatment has multiple objectives. Prevention therapy strikes a balance between iron excretion and iron absorption via blood transfusions to maintain appropriate levels of bodily iron. Rescue therapy ought to be carried out before the accumulation of hazardous levels of iron. When a patient has heart failure and needs rapid attention, emergency therapy is used. This typically involves changing or intensifying the course of treatment. In dose adjustment therapy, dosage and treatment plans are modified in response to evolving circumstances. For chelation therapy to be effective, it must be administered daily. This demands a strong dedication to the chelation protocol.
What Are the Various Chelating Agents Available at Present?
1. Deferoxamine (DFO):
The first medication administered parenterally to deal with excess iron is the DFO. Given the limited absorption of DFO through the mouth, it is more advantageous to deliver it intravenously or intramuscularly. Evidence suggests that DFO is useful in minimizing endocrine complications as well as in decreasing hepatic iron and blood ferritin levels. Improved mortality and a decrease in cardiac problems are also linked to long-term DFO therapy. Furthermore, dosages of DFO administered continuously by intravenous infusion may mitigate cardiac iron burden. The most frequent side effects of DFO include local skin responses, retarded growth, anomalies of the bones, lung issues, and neurological problems at high doses.
2. Deferiprone (DFP):
The DFP was the first iron chelator that could be used orally. Patients should receive this three times a day because it has a half-life of two to three hours and binds to iron in a proportion of three to one. Likely, the DFP works well for heart iron elimination. Agranulocytosis and gastrointestinal problems are two of the most frequent side effects that DFP patients experience. Urine iron excretion is increased by the DFP therapy. Since DFP may pass through cell membranes, it has a greater cardioprotective impact than DFO, even though total iron excretion with DFP is slightly lower than that of DFO. The DFP is particularly effective at getting rid of excess iron from the heart and other organs.
3. Deferasirox (DFX):
The FDA approved DFX in 2005, and it was the second oral iron chelator. It has a lengthy half-life and works well as an oral iron chelator. It will be used once a day to deliver the 24-hour chelation. It binds to iron in a ratio of two to one and is a tridentate iron chelator. For DFX, there are two distinct once-daily formulations available: the original formulation, DFX dispersible tablet (DT), and the more recent, DFX FCT (film-coated tablet), which was approved in 2015. Skin rashes, digestive tract complications, and elevated serum creatinine are the most common adverse events.
What Are the Future Prospects in Iron Chelation Therapy?
N-hydroxyalkyl-substituted DFP was developed as a type of iron-chelating agent for chelation therapy for Parkinson's disease. The chelator guaranteed iron affinity and satisfied Lipinski's rule for blood-brain barrier permeability.
Experts reported the first success of polymeric DFO design for the improvement of iron chelation for cancer treatment in a different recent study. By covalently coupling DFO to poly ethylene glycol poly aspartic acid (PEGPAsp) block copolymers, they were able to create polymeric DFO. As a result, in comparison to free DFO, polymeric DFO demonstrated a considerable inhibition of tumor growth.
Conclusion:
Disorders associated with iron overload have been treated using iron chelation treatment. The major goal of chelation therapy is to maintain a safe level of iron in the human body by regulating iron intake and iron excretion. It is generally advantageous to use chelating agents, and those who utilize these drugs have had good results. Iron chelation therapy helps treat iron overload and enhance longevity in general despite the paucity of available data. Ultimately, more research will soon provide comprehensive details and an understanding of iron chelation therapy.
